OBJECTIVES: Percutaneous treatment with the MitraClip device represents an alternative option for selected patients with degenerative mitral regurgitation (DMR) considered ineligible for surgery due to contraindications or high surgical risk by an inter-disciplinary heart team. We describe 12-month outcomes following treatment with the MitraClip device in DMR patients.
INTRODUCTION
Reconstructive mitral valve surgery (mitral valve repair, MVR) is the current gold standard for treatment of severe mitral regurgitation of any given aetiology according to current international guidelines [1, 2] . In patients with degenerative mitral regurgitation (DMR), surgery can be performed with low perioperative morbidity and acute mortality rates as low as 0.6% [3] . The long-term durability of modern repair techniques is excellent, with re-established life expectancy compared with an age-matched control population [4, 5] . Recently, minimally invasive surgical techniques have gained clinical importance and have decreased surgical trauma and further enhanced postoperative recovery [6] [7] [8] . Considering these results, elective MVR may be indicated even in the asymptomatic patient with severe MR [9] .
It is a clinical reality however that a large proportion of patients with severe MR are considered ineligible for surgery due to contraindications or perceived high surgical risk [10] . For these patients, transcatheter-based MVR using the MitraClip device has proven a viable alternative. Although less effective at reducing MR compared with MVR [11] , successful MitraClip therapy has been shown to effectively improve functional and clinical outcome in inoperable or high-risk patients [12] [13] [14] .
This report includes the baseline through 12-month clinical data collected in the ACCESS-EU Phase I postapproval study in a patient subset with DMR.
METHODS
The ACCESS-EU Phase I postapproval study was designed to gain information regarding the use of the MitraClip system in the European Union with respect to health economics and clinical care, and to provide further evidence of the safety and effectiveness of the MitraClip system in a real-world setting. Patient enrolment began in October 2008 and was completed in April 2011.
MitraClip procedure
The MitraClip system is a catheter-based device designed to treat MR on the beating-heart. The procedure is best performed in a hybrid cath-lab or operating suite under echocardiographic and fluoroscopic guidance and general anaesthesia, as previously described [11] . The MitraClip device is a polyester-covered cobaltchromium clip which is inserted via the femoral vein and advanced into the left atrium following trans-septal puncture. The clip is opened, positioned above the regurgitant jet and advanced into the left ventricle. With the MitraClip device centred above the origin of the regurgitant jet, the free edges of both mitral leaflets are grasped and closed to coapt the mitral leaflets across the regurgitant orifice. Adequacy of MR reduction can be assessed under physiological haemodynamic conditions and clip repositioning or placement of additional clips performed if necessary. Transthoracic echocardiograms were performed at participating sites at baseline and 12 months after MitraClip treatment, according to protocol.
Patient screening, enrolment, treatment and follow-up
Patients were assigned to MitraClip according to local institutional practice in consideration of current CE-mark-approved labeling and the MitraClip system Instructions for Use. Eligible patients included those with symptomatic MR or asymptomatic moderateto-severe (3+) or severe (4+) mitral regurgitation. Transthoracic and transoesophageal echocardiograms studies were performed by the sites at baseline to assess patient eligibility.
The ACCESS-EU study was approved by the institutional review board at each participating site, and all patients provided written informed consent prior to their participation in the study. The echocardiographic and clinical assessments were performed as per routine practice at the institutions at baseline, discharge, 6 months and 1 year after enrolment. The 6-min walk test (6MWT) and Minnesota Living with Heart Failure questionnaire (MLHFQ) were administered at baseline, 6 and 12 months. Peri-and postprocedural adverse events (AEs) were site-reported only without prospective definition of event types and without adjudication by a clinical events committee. Of 117 initially enrolled patients, 20 expired within 12 months, 9 withdrew consent and 7 missed their 12-month visit, resulting in 81 completed 12-month visits.
Statistical considerations
Results were analysed for the entire DMR cohort and additionally stratified in a post hoc manner into subgroups of patients at high or low surgical risk according to logEuroSCORE I ≥20% or <20%, respectively. Baseline and demographical qualitative variables were expressed as percentages, and quantitative variables were expressed as mean (SD) or median (25th-75th interquartile range). Serial paired data are shown for surviving patients only. MR severity and NYHA Functional Class were compared between baseline and 12-months using Bowker's test. 'The null hypothesis (H 0 : P ij = P ji ) states that the marginal probabilities for each outcome, (i.e. improvement and worsening) are the same. Rejection of the null hypothesis is evidence of lack of symmetry (H 1 : P ij ≠ P ji ), and a resulting statistically significant P-value indicates patients improved category following baseline'. Changes in 6MWT and MLHFQ between baseline and 12 months were analysed using paired t-tests. Survival rates to 12 months were presented as Kaplan-Meier curves. Differences were considered statistically significant at the 0.05 level. The data were analysed with SAS statistical software version 9.1.3 (SAS Institute, Inc., Cary, NC, USA).
RESULTS

Enrolment
Between October 2008 and April 2011, a total of 567 patients with significant mitral regurgitation were enrolled at 14 European sites and received the MitraClip device. Of these 567 patients, 117 (20.6%) were determined to have DMR. Table 1 shows baseline demographics and comorbidities for DMR patients. The overall DMR cohort was elderly (75.6 ± 12.1 years), with 61.5% of patients being over 75 years of age and 49.6%, of male gender. The majority of ACCESS-EU Phase I DMR patients presented multiple comorbidities at baseline including congestive heart failure (62.4%), coronary artery disease (41.0%), atrial fibrillation (58.8%), hypertension (75.0%), cardiomyopathy (22.6%) and moderate-to-severe renal disease (25.6%). Approximately, one quarter (24%) of the patients had previous cardiovascular surgery including coronary artery bypass grafting (17.1%), and 27.6% of patients underwent percutaneous coronary intervention prior to enrolment in the ACCESS-EU study. The vast majority of patients (96.6%) in the DMR cohort had a mitral regurgitation grade 3+ or 4+ at baseline and most (73.9%) were symptomatic with New York Heart Association (NYHA) Functional class III or IV. Mean logEuroSCORE I for the entire DMR cohort was 15.5 ± 13.3%. Stratification into high-and low-risk patients revealed important demographic differences culminating in mean logEuroSCORE I of 33.1 ± 11.5 and 8.6 ± 5.1% for the two cohorts, respectively.
Baseline characteristics
MitraClip procedure
In the ACCESS-EU DMR cohort, ≤2 MitraClip devices were successfully implanted in 94.9% of patients (111 of 117). In one high-surgical-risk patient, three MitraClip devices were required to adequately reduce MR. Two patients required mitral valve surgery on the day of the index procedure and 1 was treated by repeat MitraClip on Day 7 after initial clipping due to single leaflet device attachment discovered post-procedurally. In 3 other patients, single leaflet device attachment was noted during the index procedure.
In general, low-risk patients were more likely to receive >1 MitraClip device compared with high-surgical-risk patients (40.5% (34 of 84) vs 21.2% (7 of 33), P = 0.055).
Procedure time, contrast volume and fluoroscopy duration data are presented in Table 2 . The average procedure time was 24.0 min shorter for high-risk patients compared with low-risk patients (P = 0.1). This may be due in part to a larger proportion of low-risk patients receiving >1 MitraClip (Table 2) .
Clinical and echocardiographic outcome to 30 days
Overall, the mean duration of stay in the intensive care unit, cardiac care unit or postanaesthesia care unit following the MitraClip procedure was 2.4 ± 3.1 days, with a median of 1 (range 0-20) day. No significant difference was observed in the median acute care between high-risk and low-risk DMR patients (2.4 ± 3.8 days for high risk vs 2.4 ± 2.8 days for low risk). However, the mean post-procedural hospital stay was slightly longer for highsurgical-risk patients when compared with low-surgical-risk patients (7.2 ± 4.3 days for high risk vs 6.5 ± 5.4 days for low risk). Also, a significantly larger proportion of low-risk patients were discharged home with or without home health care than of high-risk patients (83.1 and 71.9%, respectively). One hundred and six patients were implanted with a MitraClip device and information on the severity of their MR was available at baseline and discharge; 88.7% (94 of 106) achieved an MR reduction to grade ≤2+ at discharge, and 56.6% (60 of 106) achieved an MR reduction to grade ≤1+ at discharge (P < 0.0001). The proportion of low-surgical-risk patients achieving an MR reduction to grade ≤1+ was insignificantly higher (59.7%, 46 of 77) compared with high-surgical-risk patients (48.3%, 14 of 29, P = 0.38).
Site-reported adverse events to 30 days Table 3 shows selected site-reported AEs within 30 days of the MitraClip procedure in the ACCESS-EU DMR cohort. Overall incidence of AE was 17.9% (21/117), 27.3% (9/33) and 14.3% (12/84) for high-and low-risk subgroups, respectively. This included 3 patients requiring valve reintervention (mitral valve surgery in 2 cases on the day of the index procedure, and repeat MitraClip in 1 case 7 days after the index procedure). Thirty-day mortality was 6.0% (7 of 117) with 9.1% (3 of 33) and 4.8% (4 of 84) for high-and low-risk subgroups, respectively. Causes of death were classified as cardiac in 42.9% (3 of 7) of cases as determined by the sites.
Clinical and echocardiographic outcome to 12 months
For 71 patients, echocardiographic data were available at 12 months of follow-up (Fig. 1) . Overall rate of freedom from site-assessed MR > grade 2+ was 74.6% (53 of 71). There were no statistically significant differences in high-risk, compared with low-risk, patients (80.0% (16 of 20) and 72.5% (37 of 51), P = 0.76). The majority of patients experienced improvement in heart failure symptoms and functional capacity. There was a median improvement in NYHA functional classes of one class in the total cohort (P < 0.0001) with 68% (53 of 78) of patients improving by at least one NYHA functional class. Two-or three-class improvement was observed in 20.5% (16 of 78) of patients. In the high-risk and low-risk patients, 57% (12 of 21) and 72% (41 of 57) of patients improved by at least one NYHA functional class, respectively. (P = 0.06, and P < 0.0001, respectively). Twenty-four percent (5 of 21) of high-risk and 19% (11/57) of low-risk patients experienced a two-class improvement or better in NYHA functional class. At 12 months, 80.8% (63 of 78) Adverse events (AEs) as reported by participating sites; No formal comparisons of the rates of site-reported AEs were performed between the high-risk and low-risk DMR groups. These events occurred at a low rate. The study was not powered to detect differences in these low rate events between high-risk and low-risk DMR patients.
of patients in the total cohort and 57.1% (12 of 21) and 89.5% (51 of 57) high-risk and low-risk patients, respectively, remained in NYHA functional classes I and II (Fig. 2) . Results of both 6MWT and MLHFQ improved significantly at 12 months compared with baseline. Patients improved by a mean of 77.4 metres in 6MWT (P < 0.0001) and by a mean of 13.3 units in MLHFQ (P = 0.03; Fig. 3 ).
Site-reported adverse events to 12 months
The overall incidence of AE in the entire cohort was 41.0% (48 of 117). This included 13 patients undergoing repeat valve intervention: mitral valve surgery in 9 cases at a median of 128 days (range 0-300 days) after the index procedure and repeat MitraClip placement in 4 patients at 7, 83, 182 and 198 days after the index procedure. Further AE are detailed in Table 4 . Mortality at 12 months was 17.1% (20 of 117) for the entire cohort and 24.2% (8 of 33) and 14.3% (12 of 84) for high-risk and low-risk subgroups, respectively (P (log rank) = 0.51, Fig. 4 ). Causes of death were classified as cardiac in 45% (9 of 20) cases as determined by the sites.
DISCUSSION
According to the Annual Report of the German Society for Thoracic and Cardiovascular Surgery, mortality after isolated MVR was 1.8% in 2011 in a wide spectrum of patients with MR of all aetiologies [15] . However, demographically degenerative disease is known to be the most frequent cause of severe MR in western societies. Similarly, favourable outcomes are reported throughout the literature [16, 17] , even in elderly patients [18] or in large patient samples such as in the Society of Thoracic Surgeons database where mortality after elective isolated MVR is reported at 1.2% [3] . These results of modern mitral valve surgery have to be the benchmark against which any new technique has to be judged, even though it has to be acknowledged that MitraClip therapy is a relatively young treatment that as of yet has not become a routine procedure at most centres, as opposed to surgical MVR with long-term experience in specialized centres. In the light of these excellent results after MVR, international guidelines have recently recommended the restriction of percutaneous MitraClip therapy to patients ineligible for surgery due to excessively high surgical risk or contraindications to surgery. Additionally, the interdisciplinary assessment of patients and indications for the respective treatment option is strongly encouraged [2] . In the present report, the overall risk profile was characterized by a mean logEuroSCORE I of 15.5 ± 13.3%. Stratification into high-and low-risk yielded subgroups with mean logEuroSCORE I of 33.1 ± 11.5% and 8.6 ± 5.1%. While the former group truly qualifies as high risk, the latter likely represents a group of patients rather at intermediate risk from a surgical perspective, even though logEuroSCORE I may not have captured actual risk in each individual patient. As this was a post-market registry, there were no explicit inclusion or exclusion criteria other than the presence of severe MR and eligibility for MitraClip therapy as judged by the investigators, taking into account the patients' clinical status and medical history. Therefore, the discrimination of patients who are truly inoperable as opposed to those who are at high risk for surgery was not possible in this study.
Regarding acute echocardiographic outcome with reduction of MR to grade ≤2+ in 88.7% of all patients at discharge, results were favourable compared with the recent EVEREST II trial, where this rate was reported at 77% [10] . Comparability to other reports after MitraClip therapy is difficult, as most patient populations comprise patients with mixed or pure functional MR only [19, 20] . For the low-risk patient cohort, freedom from MR ≤2+ was 89.6%, which is unsatisfactory from a surgical point of view, especially since this rate approaches near-perfect values for MVR at specialized centres [21] and since it is unequivocally known from both surgical [22] and interventional series [23] that residual MR adversely affects patient survival. Also, 30-day mortality was not negligible at 4.8% in this subgroup of patients, therefore surgical MVR remains the standard of care in patients at low to intermediate risk due to superior outcomes and proven long-term durability.
In the high-risk subgroup of patients in this report, 30-day mortality was 9.1%. Again, comparability to previous reports is hampered by different aetiologies. In the EVEREST II trial that comprised 74% of patients with DMR, 30-day mortality was 1% in the device group. However, patients were markedly younger and had a much lower prevalence of risk factors such as coronary artery disease, previous myocardial infarction, atrial fibrillation or diabetes [10] . Furthermore, logEuroSCORE I was not specified in EVEREST II. In the high-risk registry of the EVEREST II trial [13] , where 30-day mortality was 7.7%, a Society of Thoracic Surgeons (STS) score of 18.2 ± 8.0% suggests a risk profile comparable with the high-risk cohort of the present study. However, here, MR was degenerative in 41% of patients only. In reports on the real-world use of the MitraClip in high-risk patients, acute mortality rates range from 2.5 to 4.8% [11, 18, 24] .
For want of comparable MitraClip series, results in the low-risk subgroup of the present report with 14.3% mortality at 12 months have to be held against current surgical series. Even though direct comparability is impossible due to differences in patient risk profiles and even though logEuroSCORE I in this patient subgroup may not reflect true risk, these results have to be viewed critically. However, logEuroSCORE I was not calibrated to assess risk in patients with valvular heart disease, and it seems likely that these were patients in whom true risk was not adequately captured by this scoring system. When selecting patients for a MitraClip procedure who are (at least formally, as measured by logEuroSCORE I) low to intermediate risk, indication for treatment should be guided by inter-disciplinary assessment within a heart team consisting of cardiologists and cardiac surgeons as suggested by others [11] and as is recommended for high-risk patients. Regarding mortality up to 12 months of follow-up, results from the high-risk subgroup of this study seem acceptable at 24.2% compared with other MitraClip series ranging from 6 to 24.4.%, depending on risk profiles of the respective study populations [11] [12] [13] [14] .
Even though echocardiographic results appear suboptimal from a surgical standpoint, there was significant clinical benefit in the overall patient population as well as in both separate subgroups regarding NYHA functional class, and improvement in 6MWT and Minnesota Living with Heart Failure questionnaires. This observation is well supported in the literature, with similar effects in Adverse events (AEs) as reported by participating sites; No formal comparisons of the rates of site-reported AEs were performed between the high-risk and low-risk DMR groups. These events occurred at a low rate. The study was not powered to detect differences in these low rate events between high-risk and low-risk DMR patients. various types of clinical settings [10, 11, 19] and strongly supports the notion that MitraClip therapy is indicated in patients deemed inoperable or at high surgical risk to reduce symptoms and enhance quality of life. Furthermore, it is well known from the surgical literature that severity of MR has a graded impact on patient survival and that even reduction of MR from severe to moderate can be expected to yield a survival benefit [25] . Durability of MR reduction as well as clinical benefit warrant further monitoring of patients after MitraClip therapy during longer follow-up.
CONCLUSIONS
Primarily for DMR patients who are inoperable or at exceedingly high risk for surgical MVR, MitraClip therapy represents an attractive and less-invasive treatment option. The majority of patients thus treated benefit significantly regarding the severity of MR as well as clinically, regarding NYHA functional class and improvements in physical capacities and quality of life. Interventional treatment should be indicated following the discussion of patients in an inter-disciplinary conference of cardiologists and cardiac surgeons as suggested by current international guidelines.
Limitations
Patients were not randomly assigned to receive MitraClip therapy.
Outcomes of surgical and medical treatment comparator groups have not been reported to date. The process of patient selection as well as determination of the aetiology of MR were not guided by a detailed study protocol with inclusion/exclusion criteria but was rather conducted following standard local clinical practice. Thus, the eligibility of patients for MitraClip therapy may have been judged differently among participating sites. Furthermore, there were no clinical events committee definitions for important parameters such as clinical end-points (e.g. procedural success) or major adverse events. Furthermore, on-site monitoring of clinical data was limited to annual visits during the conduct of the study.
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